Informationen:
Fehler:
ID
34565
Beschreibung
Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone; ODM derived from: https://clinicaltrials.gov/show/NCT01516424
Link
https://clinicaltrials.gov/show/NCT01516424
Stichworte
Versionen (1)
- 19.01.19 19.01.19 -
Rechteinhaber
see on clinicaltrials.gov
Hochgeladen am
19. Januar 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Schizophrenia NCT01516424
Eligibility Schizophrenia NCT01516424
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Schizophrenia NCT01516424
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
ID.1
Item
subject met dsm-iv-tr criteria for a primary diagnosis of schizophrenia
boolean
ID.2
Item
patients are 18≤age≤65 years of age on the day when informed consent is obtained.
boolean
ID.3
Item
subject had a panss total score ≥70 and 120≥ at screening
boolean
ID.4
Item
subject had a score ≥4 on the panss at screening and baseline.
boolean
ID.5
Item
subjects are willing and able to comply with study protocol including treatment in hospital.
boolean
ID.6
Item
subjects or their legal guardians have signed the written informed consent form.
boolean
ID.7
Item
the subject was treatment with other investigate product within 30 days.
boolean
ID.8
Item
subject had a history of treatment with long-acting drug for anti schizophrenia within 56 days.
boolean
ID.9
Item
subject had a history of treatment with clozapine within 28 days.
boolean
ID.10
Item
subject with parkinson disease,etc
boolean